Ambu A/S (AMBBY)
| Market Cap | 2.69B -43.4% |
| Revenue (ttm) | 941.66M +4.6% |
| Net Income | 73.59M +28.9% |
| EPS | 0.28 +29.6% |
| Shares Out | n/a |
| PE Ratio | 36.54 |
| Forward PE | 24.54 |
| Dividend | 0.03 (0.35%) |
| Ex-Dividend Date | Dec 5, 2025 |
| Volume | 3,251 |
| Average Volume | 640 |
| Open | 9.58 |
| Previous Close | n/a |
| Day's Range | 9.58 - 9.58 |
| 52-Week Range | 9.58 - 16.78 |
| Beta | 1.26 |
| RSI | 31.37 |
| Earnings Date | May 6, 2026 |
About Ambu A/S
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronc... [Read more]
Financial Performance
In fiscal year 2025, Ambu A/S's revenue was 6.04 billion, an increase of 11.98% compared to the previous year's 5.39 billion. Earnings were 609.00 million, an increase of 159.15%.
Financial numbers in DKK Financial StatementsNews
Ambu A/S Transcript: Q2 25/26
Endoscopy Solutions drove strong growth, offsetting A&PM declines, with guidance narrowed to 10%-12% revenue growth and EBIT margin maintained at 12%-14%. Share buyback expanded to DKK 450 million, and H2 is expected to see higher growth and margins.
Ambu A/S Quarterly report: Q2 2026
Ambu A/S has published its Q2 2026 quarterly earnings report on May 6, 2026.
Ambu A/S Slides: Q2 2026
Ambu A/S has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Ambu A/S Transcript: Q1 25/26
Q1 delivered 8.6% organic revenue growth, led by endoscopy (14.4%) and strong urology/respiratory momentum. EBIT margin was 10.5% (adjusted >15% excluding tariffs/FX), with full-year guidance maintained and tariff/FX headwinds expected to ease in H2.
Ambu A/S Quarterly report: Q1 2026
Ambu A/S has published its Q1 2026 quarterly earnings report on February 4, 2026.
Ambu A/S Slides: Q1 2026
Ambu A/S has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 4, 2026.
Ambu A/S Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong double-digit growth and a successful turnaround have positioned the company as a leader in single-use endoscopy, with a focus on respiratory and urology. Innovation, scalable operations, and a robust financial outlook support continued expansion, while competition and market conversion drive future growth.
Ambu A/S Slides: SEB Nordic Seminar presentation
Ambu A/S has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Ambu A/S Transcript: Q4 24/25
Delivered 13.1% organic revenue growth and 13.0% EBIT margin, driven by strong endoscopy and anesthesia segments. Outlook for 2025-2026 is 10%-13% organic growth and 12%-14% EBIT margin, with tariffs and FX as key headwinds but long-term targets reaffirmed.
Ambu A/S Annual report: Q4 2025
Ambu A/S has published its Q4 2025 annual report on November 5, 2025.
Ambu A/S Quarterly report: Q4 2025
Ambu A/S has published its Q4 2025 quarterly earnings report on November 5, 2025.
Ambu A/S Slides: Q4 2025
Ambu A/S has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on November 5, 2025.
Ambu A/S Transcript: CMD 2025
A new growth strategy targets global endoscopy leadership through single-use innovation, digital solutions, and operational scale. Financial guidance is raised to 11%-13% organic CAGR and 20%+ EBIT margin by 2029/30, with disciplined M&A and a strong focus on people, sustainability, and customer-centricity.
Ambu A/S Slides: FY 2025
Ambu A/S has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 1, 2025.
Ambu A/S Transcript: Q3 24/25
Q3 delivered strong organic growth and margin expansion, with guidance raised for full-year revenue. FX headwinds and higher working capital impacted margins and cash flow, but operational leverage and new product launches support a positive outlook.
Ambu A/S Quarterly report: Q3 2025
Ambu A/S has published its Q3 2025 quarterly earnings report on August 22, 2025.
Ambu A/S Slides: Q3 2025
Ambu A/S has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on August 22, 2025.
Ambu initiated with a Buy at UBS
UBS analyst Thyra Lee initiated coverage of Ambu (AMBFF) with a Buy rating and DKK 147 price target The company is set to deliver mid-teens sales and mid-20s earnings growth,…
Ambu A/S Transcript: Q2 24/25
Delivered 15.4% organic revenue growth in the first half and 11.7% in Q2, with EBIT margin at 14.4% for the quarter. Maintains full-year guidance despite tariff and currency risks, supported by strong product launches and manufacturing flexibility.
Ambu A/S Quarterly report: Q2 2025
Ambu A/S has published its Q2 2025 quarterly earnings report on May 7, 2025.
Ambu A/S Slides: Q2 2025
Ambu A/S has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on May 7, 2025.
Ambu A/S Transcript: Q1 24/25
Q1 saw 19.5% organic revenue growth and a 16.1% EBIT margin, driven by strong performance in Endoscopy Solutions and Anesthesia/Patient Monitoring. Guidance for the year was raised, with new product launches and operational efficiencies supporting future growth.
Ambu A/S Quarterly report: Q1 2025
Ambu A/S has published its Q1 2025 quarterly earnings report on January 30, 2025.
Ambu A/S Slides: Q1 2025
Ambu A/S has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on January 30, 2025.
Ambu A/S Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Endoscopy solutions achieved nearly 20% growth and now comprise 60% of revenue, with strong gains in pulmonology, urology, and ENT. New product launches and a unified software platform support continued leadership, while operational improvements and a debt-free position enable investment in growth. Guidance was raised following a robust Q1.